8th Annual Innate Killer Summit
Join us at the 8th Annual Innate Killer Summit in La Jolla, CA from March 28- 30! Our team of experts will be on site…
Read more
Biocytogen to Host 1-on-1 Meetings at BIO-EUROPE SPRING® 2023
Biocytogen’s antibody BD and licensing team is pleased to attend and host 1-on-1 meetings at the 17th annual BIO-Europe Spring, taking place March 20–22, 2023…
Read more
AACR 2023
We're attending AACR 2023, held from April 14-19 in Orlando, Florida! For the latest advances, service offerings, and promotions, register now to visit our team…
Read more
Festival of Biologics – USA
Join us at the The Festival of Biologics USA in San Diego, CA from March 20- 22! Learn more about our antibody discovery capabilities and…
Read more
March 2023 Newsletter
New Animal Models Humanized Immune-Checkpoint Mice Catalog Number Product 112252 B-hTIGIT mice(C) 110926 B-hDLL3 mice 112067 B-hDLL4 mice 112666 B-hCD3E/hCD20/hCD38 mice 111091 B-hCD23 mice 111242…
Read more
Biocytogen Announces RenLite® Licensing Agreement with Janssen
BEIJING, March 8, 2023 -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen Biotech,…
Read more
7th Annual MarketsandMarkets Next-Gen Immuno-Oncology Conference
Join us at the 7th Annual MarketsandMarkets Next Gen Immuno-Oncology Conference in in London, UK from March 9-10, 2023! Whether you need humanized models, PK/PD…
Read more
Biocytogen to Highlight Bispecific ADC Pipeline at World ADC London 2023
Biocytogen is excited to attend and deliver oral and poster presentations at the upcoming 13th World ADC London conference, held on March 13th-16th, 2023. Dr.…
Read more
Biocytogen’s Subsidiary Eucure Biopharma and Chipscreen Biosciences’ Holding Subsidiary Chipscreen NewWay Biosciences Enter into Greater China License Agreement for Bispecific Antibody YH008
BEIJING, China, February 27, 2023 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that its wholly owned subsidiary, Eucure (Beijing) Biopharma Co.,…
Read more
Biocytogen Launches “Nano 100 Project” to Develop Fully Human Nanobody Therapeutics for Over 100 Targets
BEIJING, China, February 21, 2023 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced the launch of the “Nano 100 Project”, which aims…
Read more